Caleb received a B.S. Degree in Biochemistry and Molecular Biology from Penn State University and a Ph.D. in Biophysical Chemistry from Stanford University. He completed the Stanford Graduate School of Business Ignite Program. Caleb's research interests include anaerobic microbiology, biological magnetic phenomena and various spectroscopic methods for biochemical and biomedical research. He founded two companies prior to Bell Biosystems, Inc., an

Dan received a degree in Business Administration and Operations Management from Drexel University. Prior to co-founding Bell Biosystems, Dan held various management positions at startups and multi-national companies with his most recent focus in the retail energy space. His business experience includes years of start-up ventures, successful multi-million dollar product launches, customer and supply chain management, regulatory compliance and fina

Thirty years of experience in the biotechnology, cell therapy, and medical device industries. Ken co-Founded TotipotentRX Corp. in 2008, and served as its Chairman & CEO before merging the company with ThermoGenesis Corp. - uplisting the merged entity as Cesca Therapeutics on the Nasdaq exchange. Ken was the President and Board Director of Cesca, and led the company to FDA approval for a pivotal clinical trial in a cardiovascular indication.